08:00 , Dec 16, 2013 |  BioCentury  |  Strategy

Out in the cold

New excluded drugs lists devised by pharmacy benefits managers are raising the hurdle for reimbursement of drugs the PBMs' pharmacy and therapeutics committees consider to be clinically equivalent to cheaper drugs. Drugs that are not...
08:00 , Mar 5, 2012 |  BC Week In Review  |  Clinical News

Altoprev lovastatin XL regulatory update

FDA approved several label changes for the statin class of cholesterol drugs, including eliminating the need for routine periodic monitoring of liver enzymes. The labels now recommend that liver enzyme tests should be performed before...
02:07 , Feb 29, 2012 |  BC Extra  |  Company News

FDA updates statin labels

FDA approved several label changes for the statin class of cholesterol drugs, including eliminating the need for routine periodic monitoring of liver enzymes. The labels now recommend that liver enzyme tests should be performed before...
07:00 , Apr 20, 2009 |  BC Week In Review  |  Clinical News

Altoprev lovastatin XL: Post-marketing study data

AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.   Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y.   Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J.   Pfizer Inc. (NYSE:PFE), New York, N.Y.   Shionogi & Co. Ltd., Osaka, Japan   Product: ...
07:00 , Mar 23, 2009 |  BC Week In Review  |  Clinical News

Advicor extended release lovastatin/niacin data

In a retrospective, post-marketing analysis of 6,574 adults taking corticosteroids for asthma, patients who also received statin treatment for a cardiovascular condition had a lower rate of hospitalization or ER visit for asthma over 12...
07:00 , Apr 4, 2005 |  BC Week In Review  |  Company News

Andrx, First Horizon Pharmaceutical Co. deal

FHRX completed its previously announced acquisition of ADRX's Fortamet extended-release metformin to treat Type II diabetes and Altoprev extended-release lovastatin for cholesterol disorders (see BioCentury, March 7). FHRX paid ADRX $50 million and may...
08:00 , Mar 7, 2005 |  BC Week In Review  |  Company News

Andrx, First Horizon deal

Fortamet posted $4.5 million in sales for the third quarter of 2004, while sales for Altoprev (previously called Altocor) were not broken out. In January, ADRX announced plans to exit the branded products space...
03:33 , Mar 3, 2005 |  BC Extra  |  Company News

First Horizon acquires two Andrx drugs

FHRX will acquire U.S. rights to Fortamet extended-release metformin and Altoprev extended-release lovastatin from ADRX for $50 million up front. Fortamet, which was launched in May 2004 to treat Type II diabetes, had $4.5 million...
07:00 , Sep 30, 2002 |  BC Week In Review  |  Clinical News

Altocor lovastatin XL: Phase II data; marketed to prevent coronary heart disease

In a placebo-controlled, double-blind Phase II trial in AD patients, 20-80 mg Altocor gave a 30%-44% reduction in low-density lipoprotein cholesterol (LDL-C), an 18%-31% reduction in total cholesterol and a 17%-19% reduction in triglycerides. The...
08:00 , Feb 4, 2002 |  BC Week In Review  |  Clinical News

Altocor extended-release lovastatin regulatory update

ADRX received an approvable letter from the FDA for its NDA for Altocor lovastatin XL to treat hypercholesterolemia. Altocor, an inhibitor of HMG-CoA reductase, uses ADRX's SCOT controlled-release technology to deliver lovastatin to the liver....